Go Pro

Stephen Brozak Analyst Performance

Analyst at WBB Securities

Stephen Brozak is a stock analyst at WBB Securities focused in the healthcare sector, covering 9 publicly traded companies. Over the past year, Stephen Brozak has issued 6 stock ratings, including strong buy and buy recommendations. While full access to Stephen Brozak's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Stephen Brozak's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
29 Last 12 Years
Buy Recommendations
100.00% 29 Buy Ratings
Companies Covered
9 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy37.9%11 ratings
Buy62.1%18 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

Out of 29 total stock ratings issued by Stephen Brozak at WBB Securities, the majority (62.1%) have been Buy recommendations, followed by 37.9% Strong Buy.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
9 companies

Stephen Brozak, an analyst at WBB Securities, currently covers 9 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
8 companies
88.9%
Miscellaneous
1 company
11.1%

Stephen Brozak of WBB Securities specializes in stock coverage within the Healthcare sector, with additional focus on companies.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
6 companies
66.7%
Miscellaneous
1 company
11.1%
HEALTHCARE EQUIPMENT & SUPPLIES
1 company
11.1%
PHARMACEUTICALS
1 company
11.1%

Stephen Brozak's Ratings History at WBB Securities

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Vogenx Inc stock logo
VOGX
Vogenx
9/2/2026Initiated Coverage$33.32$42.00Speculative Buy
Vogenx Inc stock logo
VOGX
Vogenx
9/2/2026Initiated Coverage$32.15$42.00Speculative Buy
Omeros Corporation stock logo
OMER
Omeros
10/15/2025Reiterated Rating$10.20$45.00Strong-Buy
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
10/9/2025Boost Price Target$107.67$199.00Strong-Buy
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
9/22/2025Reiterated Rating$68.71$123.00Strong-Buy
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
9/22/2025Boost Price Target$68.71$123.00Strong-Buy
Celularity, Inc. stock logo
CELU
Celularity
9/9/2025Upgrade$2.19$6.00Buy
Celularity, Inc. stock logo
CELU
Celularity
8/18/2025Initiated Coverage$3.75$6.00Moderate Buy
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
6/23/2025Reiterated Rating$40.74$45.00Strong-Buy
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
4/1/2025Reiterated Rating$1.23$12.50Strong-Buy